Close Menu

Jim Manzi, Steve Lundy

Premium
Thermo Fisher Scientific this week named Jim Manzi non-executive chairman of its board. He succeeds Paul Meister, who retired as chairman on April 10. Manzi was chairman of Thermo Electron from December 2003 through Nov. 9, 2006, when Thermo completed its merger with Fisher Scientific. He is currently chairman of Stonegate Capital. He was president, chairman, and CEO of Lotus Development from 1984 to 1995, when it was acquired by IBM.
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.